Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia

2025

Efficacy and Safety of Sequential CD19 and CD22 CAR-T Therapy in Adult B-ALL

Sample size: 23 publication Evidence: moderate

Author Information

Author(s): Tingting Yang, Yetian Dong, Mingming Zhang, Jingjing Feng, Shan Fu, Pingnan Xiao, Ruimin Hong, Huijun Xu, Jiazhen Cui, Simao Huang, Guoqing Wei, Delin Kong, Geng Jia, Alex H. Chang

Primary Institution: First Affiliated Hospital of Zhejiang University

Hypothesis

This study aimed to evaluate the efficacy and safety of sequential CD19 and CD22 CAR-T cell therapy in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Conclusion

Sequential CAR-T cell therapy demonstrated durable efficacy and a manageable safety profile in relapsed/refractory B-ALL.

Supporting Evidence

High-risk cytogenetic and genomic aberrations were identified in 43.5% of patients.
The median overall survival was not reached with a median follow-up of 19.4 months.
91.3% of patients were alive at 1 year, and 58.6% at 2 years.
Leukemia-free survival rates were 67.1% at 1 year and 47.0% at 2 years.
Cytokine release syndrome occurred in 78.3% of patients after CD19 CAR-T therapy.

Takeaway

This study shows that using two types of CAR-T therapy can help adults with a tough type of leukemia feel better and live longer.

Methodology

The study evaluated the efficacy and safety of sequential CD19 and CD22 CAR-T cell therapy in adult patients with R/R B-ALL, focusing on adverse events, overall survival, and leukemia-free survival.